Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

321.59
+1.630.51%
Post-market: 321.890.3000+0.09%19:53 EDT
Volume:178.44K
Turnover:57.42M
Market Cap:19.35B
PE:34.91
High:324.79
Open:323.08
Low:320.54
Close:319.96
52wk High:330.75
52wk Low:249.57
Shares:60.18M
Float Shares:60.18M
Volume Ratio:0.87
T/O Rate:0.30%
Dividend:4.74
Dividend Rate:1.47%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.98
PE(LYR):7.75

Loading ...

Moderna Stock Price Doubles on Melanoma Vaccine News

Dow Jones
·
Aug 19

Merck Shares Touch Record High, Last up 9.6%

THOMSON REUTERS
·
Aug 19

Shares of Moderna Rise 87%, Merck Rise 6.8% After Skin Cancer Vaccine Succeeds in Late-Stage Trial

THOMSON REUTERS
·
Aug 19

Sector Update: Healthcare

MT Newswires Live
·
Aug 19

Biotech Stocks Jump Premarket After Moderna's Melanoma Vaccine with Merck Succeeds in Large Trial

THOMSON REUTERS
·
Aug 19

The Bond Selloff is Rattling Investors, but Here's Why They Shouldn't Expect a Deeper Stock Downturn

Dow Jones
·
Aug 19

Stocks to Watch: Oracle, SK Hynix, Moderna, Unitree

Dow Jones
·
Aug 19

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market

Dow Jones
·
Aug 19

U.S. Stocks on the MOVE-Estee Lauder, Target, Analog Devices

Reuters
·
Aug 19

Merck, Moderna Say Potential Melanoma Therapy Shows 'Statistically Significant Improvement' in Late-Stage Trial

MT Newswires Live
·
Aug 19

Bond Yields, Persian Gulf Outlooks Cap Wall Street Pre-Bell; Asia, Europe Off

MT Newswires Live
·
Aug 19

Moderna Stock Surges 70%, Merck Rises 6%. at Last, a Successful Cancer Vaccine.

Dow Jones
·
Aug 19

Moderna and Merck Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Moderna Vaccine Cuts Recurrence and Spread of High-Risk Melanoma, Raising New Treatment Hope

Reuters
·
Aug 19

Merck Shares Rise 1.9% Premarket

THOMSON REUTERS
·
Aug 19

Merck, Moderna Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Merck: Safety Profiles of Intismeran and Keytruda in Trial were Consistent with Prior Reported Studies for the Combination

THOMSON REUTERS
·
Aug 19

Merck: Phase 3 Interpath-001 Trial of Intismeran Autogene Plus Keytruda Met Primary Endpoint of Recurrence Free Survival

THOMSON REUTERS
·
Aug 19

Merck: Co, Moderna Announce Positive Results from Phase 3 Interpath-001 Trial for Patients with Completely Resected Stage Iib-Iv Melanoma

THOMSON REUTERS
·
Aug 19

Merck: Co, Moderna Will Engage with Regulators on Filing Submissions for Intismeran Autogene in Combination with Keytruda

THOMSON REUTERS
·
Aug 19